Loading...
•
Jun 30, 2022
Ocular Therapeutix Q2 2022 Earnings Report
Ocular Therapeutix reported a net revenue increase of 5% year-over-year, driven by DEXTENZA sales, and is progressing with its ophthalmology pipeline.
Key Takeaways
Ocular Therapeutix reported its second quarter 2022 financial results, with net revenue of $12.3 million, a 5% increase compared to the same period in 2021. DEXTENZA net product revenue reached $12.1 million, representing a 9% increase year-over-year. The company is advancing its ophthalmology pipeline, with interim data from the OTX-TKI clinical trial expected in the third quarter.
Net revenue for the second quarter was $12.3 million, a 5% increase year-over-year.
DEXTENZA net product revenue reached $12.1 million, a 9% increase year-over-year.
A net loss of $(18.8) million, or $(0.24) and $(0.25) per share on a basic and diluted basis, respectively, was reported for the quarter.
Interim data from the U.S.-based Phase 1 clinical trial of OTX-TKI for the treatment of wet AMD is expected in the third quarter.
Revenue by Segment
Forward Guidance
Ocular Therapeutix reiterated DEXTENZA annual net product revenue guidance for 2022 between $55 to $60 million, representing annual growth of approximately 26% to 38%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...